Annual report pursuant to Section 13 and 15(d)

Collaboration and Research Arrangements - Summary of Changes in Contract Assets and Liabilities (Details)

v3.22.0.1
Collaboration and Research Arrangements - Summary of Changes in Contract Assets and Liabilities (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
Disaggregation Of Revenue [Line Items]  
Accounts receivable and contract assets, Balance at Beginning of Period $ 2,331
Accounts receivable and contract assets, Additions 22,341
Accounts receivable and contract assets, Deductions (21,693)
Accounts receivable and contract assets, Balance at End of Period 2,979
Contract liabilities, Balance at Beginning of Period 22,086
Contract liabilities, Additions 174
Contract liabilities, Deduction (12,079)
Contract liabilities, Balance at End of Period 10,181
Incyte  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 5,365
Contract liabilities, Deduction (4,097)
Contract liabilities, Balance at End of Period 1,268
Global Blood Therapeutics  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 16,721
Contract liabilities, Additions 174
Contract liabilities, Deduction (7,982)
Contract liabilities, Balance at End of Period 8,913
Billed receivables from collaboration partners  
Disaggregation Of Revenue [Line Items]  
Accounts receivable, Balance at Beginning of Period 7
Accounts receivable, Additions 10,931
Accounts receivable, Deduction (10,938)
Unbilled receivables from collaboration partners  
Disaggregation Of Revenue [Line Items]  
Contract assets, Balance at Beginning of Period 2,324
Contract assets, Additions 11,410
Contract assets, Deduction (10,755)
Contract assets, Balance at End of Period $ 2,979